Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial-Reference-Cited by-同舟云学术

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

Published:2013-05-27 Issue:31 Volume:34 Page:2453-2463
ISSN:1522-9645
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Pitt Bertram,Kober Lars,Ponikowski Piotr,Gheorghiade Mihai,Filippatos Gerasimos,Krum Henry,Nowack Christina,Kolkhof Peter,Kim So-Young,Zannad Faiez

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/article-pdf/34/31/2453/17896659/eht187.pdf

Reference17 articles.

1. Eplerenone in patients with systolic heart failure and mild symptoms;Zannad;N Engl J Med,2011

2. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators;Pitt;N Engl J Med,1999

3. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC;McMurray;Eur Heart J,2012

4. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation;Hunt;J Am Coll Cardiol,2009

5. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases;Bärfacker;ChemMedChem,2012

Cited by 450 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Finerenone: A Novel Drug Discovery for the Treatment of Chronic Kidney Disease;Current Drug Discovery Technologies;2024-11

2. Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China;Renal Failure;2024-09-09

3. A four-in-one first-in-human study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship of HRS-1780, a selective non-steroidal mineralocorticoid receptor antagonist, in healthy men;Expert Opinion on Investigational Drugs;2024-08-26

4. Clinical Properties and Non-Clinical Testing of Mineralocorticoid Receptor Antagonists in In Vitro Cell Models;International Journal of Molecular Sciences;2024-08-22

5. Cardio-reno-vascular protection in type 2 diabetes mellitus: new insights into pharmacotherapeutic management;Expert Opinion on Pharmacotherapy;2024-08-12